LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Затворен

СекторЗдравеопазване

15.44 2.86

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.02

Максимум

15.49

Ключови измерители
By Trading Economics
Приходи	-130B -25B
Продажби	-99B 1.1T
P/E Средно за сектора	39.974 49.888
EPS	0.21
Дивидентна доходност	4.35
Марж на печалбата	-2.222
Служители	47,455
EBITDA	-242B 214B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+39.72% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	4.35% 2.38%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.7B 48B
Предишно отваряне	12.58
Предишно затваряне	15.44

Настроения в новините

By Acuity

100%

325 / 344 Класиране в Healthcare

Takeda Pharmaceutical Co Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2026 г., 08:59 ч. UTC

Печалби

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29.01.2026 г., 07:11 ч. UTC

Печалби

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19.12.2025 г., 03:32 ч. UTC

Значими двигатели на пазара

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30.10.2025 г., 09:39 ч. UTC

Печалби

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30.10.2025 г., 07:32 ч. UTC

Печалби

Takeda Posts Quarterly Net Loss, Cuts Guidance

13.05.2026 г., 06:57 ч. UTC

Печалби

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13.05.2026 г., 06:54 ч. UTC

Печалби

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13.05.2026 г., 06:44 ч. UTC

Печалби

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13.05.2026 г., 06:38 ч. UTC

Печалби

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13.05.2026 г., 06:31 ч. UTC

Печалби

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13.05.2026 г., 06:31 ч. UTC

Печалби

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13.05.2026 г., 06:31 ч. UTC

Печалби

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13.05.2026 г., 06:31 ч. UTC

Печалби

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13.05.2026 г., 06:31 ч. UTC

Печалби

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13.05.2026 г., 06:31 ч. UTC

Печалби

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29.01.2026 г., 06:53 ч. UTC

Печалби

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29.01.2026 г., 06:36 ч. UTC

Печалби

Takeda Raises FY Revenue, Net-Profit Views

29.01.2026 г., 06:34 ч. UTC

Печалби

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29.01.2026 г., 06:33 ч. UTC

Печалби

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29.01.2026 г., 06:32 ч. UTC

Печалби

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29.01.2026 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29.01.2026 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29.01.2026 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29.01.2026 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29.01.2026 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29.01.2026 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30.10.2025 г., 07:10 ч. UTC

Печалби

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30.10.2025 г., 06:50 ч. UTC

Печалби

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30.10.2025 г., 06:49 ч. UTC

Печалби

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30.10.2025 г., 06:48 ч. UTC

Печалби

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Сравнение с други в отрасъла

Ценова промяна

Takeda Pharmaceutical Co Ltd ADR Прогноза

Ценова цел

By TipRanks

39.72% нагоре

12-месечна прогноза

Среден 21 USD 39.72%

Висок 21 USD

Нисък 21 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Takeda Pharmaceutical Co Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Takeda Pharmaceutical Co Ltd ADR през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.